JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study

(2017) Jean-Christophe Ianotto et al.   HAEMATOLOGICA

Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes

(2017) Lasse Kjaer et al.   LEUKEMIA & LYMPHOMA

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study

(2017) Jean-Christophe Ianotto et al.   HAEMATOLOGICA

Canonical and Non-Canonical Aspects of JAK–STAT Signaling: Lessons from Interferons for Cytokine Responses

(2017) Andrea Majoros et al.   Frontiers in Immunology

Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms

(2016) M. Araki et al.   BLOOD

Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms

(2016) William Vainchenker et al.   BLOOD

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Response to interferons and antibacterial innate immunity in the absence of tyrosine‐phosphorylated STAT1

(2016) Andrea Majoros et al.   EMBO REPORTS

Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion

(2016) Lijuan Han et al.   Journal of Hematology & Oncology

Thrombopoietin receptor is required for the oncogenic function of CALR mutants

(2016) H Nivarthi et al.   LEUKEMIA

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both

(2016) S Koschmieder et al.   LEUKEMIA

Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment

(2016) Lasse Kjær et al.   PLoS One

Long-acting interferon for myeloproliferative neoplasms - an update

(2016) Sachin Gopalkrishna Pai et al.   Expert Review of Hematology

Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation

(2016) S. Elf et al.   Cancer Discovery

STAT2 Is a Pervasive Cytokine Regulator due to Its Inhibition of STAT1 in Multiple Signaling Pathways

(2016) Johnathan Ho et al.   PLOS BIOLOGY

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b

(2015) Nicole C.C. Them et al.   AMERICAN JOURNAL OF HEMATOLOGY

Clinical and molecular response to interferon-  therapy in essential thrombocythemia patients with CALR mutations

(2015) E. Verger et al.   BLOOD

Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants

(2015) I. Chachoua et al.   BLOOD

Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis

(2015) C. Marty et al.   BLOOD

Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone

(2015) J-J Kiladjian et al.   LEUKEMIA

MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives

(2015) Hans Carl Hasselbalch et al.   MEDIATORS OF INFLAMMATION

limma powers differential expression analyses for RNA-sequencing and microarray studies

(2015) Matthew E. Ritchie et al.   NUCLEIC ACIDS RESEARCH

Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms

(2015) Honghe Wan et al.   ACS Medicinal Chemistry Letters

Presence of calreticulin mutations in JAK2-negative polycythemia vera

(2014) J. Broseus et al.   BLOOD

Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia

(2014) Bruno Cassinat et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy

(2014) Helen L. Wright et al.   RHEUMATOLOGY

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

(2013) A. Tefferi et al.   BLOOD

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon  -2a

(2013) A. Quintas-Cardama et al.   BLOOD

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enriching the gene set analysis of genome-wide data by incorporating directionality of gene expression and combining statistical hypotheses and methods

(2013) Leif Väremo et al.   NUCLEIC ACIDS RESEARCH

A Fusion Cytokine Coupling GMCSF to IL9 Induces Heterologous Receptor Clustering and STAT1 Hyperactivation through JAK2 Promiscuity

(2013) Pingxin Li et al.   PLoS One

Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy

(2012) Priya Koppikar et al.   NATURE

Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent

(2012) Rita Andraos et al.   Cancer Discovery

Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease

(2011) C. Elling et al.   BLOOD

Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFN  via accelerating the degradation of its receptor

(2011) S. Bhattacharya et al.   BLOOD

Suppressor of Cytokine Signaling (SOCS) 1 Inhibits Type I Interferon (IFN) Signaling via the Interferon α Receptor (IFNAR1)-associated Tyrosine Kinase Tyk2

(2011) Rebecca A. R. Piganis et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

STAT3 Negatively Regulates Type I IFN-Mediated Antiviral Response

(2011) W.-B. Wang et al.   JOURNAL OF IMMUNOLOGY

Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2

(2011) A V Purandare et al.   LEUKEMIA

Distinct Clinical Phenotypes Associated with JAK2V617F Reflect Differential STAT1 Signaling

(2010) Edwin Chen et al.   CANCER CELL

Activation of JAK2-V617F by Components of Heterodimeric Cytokine Receptors

(2010) Anuradha Pradhan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference

(2009) G. Barosi et al.   BLOOD